Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study found that big chain pharmacies in Pennsylvania charged significantly higher prices for generic BPH medications compared to independent pharmacies, which had more regional price variation.

Plant-based treatments may help reduce BPH symptoms, but more research is needed.

This study demonstrated that methylation of the 5-alpha reductase type 2 (5-AR2) promoter is linked to reduced expression of the 5-AR2 protein, possibly explaining resistance to Finasteride in some BPH patients.

This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This study investigates the potential influence of genetic variations in the 5α-reductase type 2 gene on the effectiveness of finasteride treatment for benign prostatic hyperplasia, but it reports no new clinical results.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This case-control study from Lombardy, Italy, observed that men over 55 taking 5-alpha reductase inhibitors for benign prostatic hyperplasia were hospitalized for COVID-19 at a lower rate than age-matched controls, suggesting potential protective effects against severe disease.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.

This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

This review discusses the impact of COVID-19 on urological treatment approaches, including the heightened severity of LUTS in men with urological issues and emphasizes the importance of adhering to treatment protocols.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This study found that using anhydrous cerium(III) chloride with alkyl Grignard reagents significantly improved the addition to sterically hindered 17-ketosteroids, resulting in high yields and stereoselectivity.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

A new compound that could treat various androgen-related conditions was created and analyzed.